CVRx price target raised to $23 from $22 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on CVRx to $23 from $22 and keeps a Buy rating on the shares. The analyst said we expect CVRx to leverage the totality of the M&M data from the primary endpoint and/or the pre-specified additional analyses to further drive adoption of Barostim therapy through HF specialist acceptance and possibly more favorable payer coverage.